Alzheimer’s disease is a progressive neurodegenerative disorder characterized by amyloid-beta plaques, tau neurofibrillary tangles, synaptic loss, neuroinflammation, and declining acetylcholine and BDNF levels. These changes produce the memory loss, cognitive decline, and personality changes of the disease. Peptide research approaches Alzheimer’s by promoting synaptogenesis, reducing neuroinflammation, providing neurotrophic support, and protecting neurons from the oxidative and inflammatory damage driving progressive degeneration.
1. Dihexa — Synaptogenesis / Cognitive Restoration
Dihexa is an angiotensin IV analog developed specifically for Alzheimer’s research at Washington State University. It is estimated to be up to 10 million times more potent than BDNF at promoting synaptogenesis — the formation of new neural connections. Animal models of Alzheimer’s show dramatic reversal of cognitive deficits with Dihexa, including restoration of spatial memory and learning — making it arguably the most exciting peptide in neurodegeneration research.
Dosing Protocol: 10–15 mg oral (compounded capsule) daily, or 1–3 mg SubQ. Cycle: 4–8 weeks. Structural synaptic effects may persist after discontinuation.
2. Semax — BDNF / NGF Upregulation / Neuroprotection
Semax dramatically upregulates BDNF, NGF, and VEGF — neurotrophic factors critically depleted in Alzheimer’s brains. It enhances cerebral blood flow, reduces neuroinflammation, and provides neuroprotection against the amyloid-beta-induced oxidative and excitotoxic damage driving neuronal loss. Semax also improves cholinergic neurotransmission — the system most devastated in Alzheimer’s.
Dosing Protocol: 300–600 mcg intranasal daily (split AM/midday). SubQ: 300–500 mcg daily. Cycle 10 days on / 5 days off for extended use.
3. Cerebrolysin — Neuropeptide Support / Amyloid Modulation
Cerebrolysin is a standardized mixture of neuropeptides approved in multiple countries for Alzheimer’s disease treatment. It reduces amyloid precursor protein processing, decreases tau phosphorylation, promotes neuronal survival and plasticity, and has demonstrated cognitive improvement in multiple randomized controlled trials in Alzheimer’s patients.
Dosing Protocol: 5–10 mL IV or IM daily for 20-day courses, 2–4x per year. Lower doses (2–5 mL IM) for maintenance between courses. Best administered in a clinical setting.
4. SS-31 (Elamipretide) — Mitochondrial Protection / ROS Reduction
Mitochondrial dysfunction is now recognized as an early and primary driver of Alzheimer’s pathology — preceding amyloid plaque formation. SS-31 protects neuronal mitochondrial membranes from oxidative damage, restores ATP production in neurons, and reduces the mitochondrial ROS that accelerates amyloid production and tau phosphorylation. It addresses the energetic crisis underlying neuronal death.
Dosing Protocol: 1–3 mg SubQ daily. Clinical doses 0.05–0.25 mg/kg IV. Cycle: 4–8 weeks.
Dihexa directly builds new synaptic connections to replace those lost to Alzheimer’s pathology — the most impactful structural intervention available. Semax maintains the BDNF and neurotrophic environment that sustains those connections and protects remaining neurons. Cerebrolysin provides a clinically validated multi-neuropeptide support mixture that modulates amyloid and tau pathology while directly nurturing neuronal survival. SS-31 addresses the mitochondrial energy crisis that is both a cause and amplifier of Alzheimer’s neurodegeneration — ensuring neurons have the ATP needed to maintain function and resist pathological protein accumulation.
- McCoy MK et al. (2012). Dihexa and synaptogenesis in Alzheimer models. Science Translational Medicine. DOI: 10.1126/scitranslmed.3002381
- Eremin KO et al. (2012). Semax BDNF and neuroprotection. Biochemistry (Moscow). DOI: 10.1134/S0006297912130093
- Alvarez XA et al. (2006). Cerebrolysin in Alzheimer’s disease — randomized trial. Annals of Neurology. DOI: 10.1002/ana.20271
- Szeto HH et al. (2014). SS-31 and neuronal mitochondrial protection. Journal of Molecular and Cellular Cardiology. DOI: 10.1016/j.yjmcc.2013.04.010
- Masliah E et al. (2012). Cerebrolysin effects on amyloid and tau in Alzheimer’s. Journal of Alzheimer’s Disease. DOI: 10.3233/JAD-2012-120736
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).